Articles

Find an Article

Filter articles

Applied Filters

Showing 61 to 70 of 322 results

LSIPR 50 2018: Donald Trump

US26-07-2018

Donald Trump was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Bernard Tyson

US25-07-2018

Bernard Tyson was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Patrick Leahy

US23-07-2018

Patrick Leahy was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Raymond Chen and Kathleen O’Malley

US20-07-2018

Raymond Chen and Kathleen O’Malley were selected in the LSIPR 50 2018 publication for​ ​their influence on the life sciences industry. They featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Scott Gottlieb

US19-07-2018

Scott Gottlieb was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Backing the innovators

US17-07-2018

Josh Makower, partner at venture capital investor New Enterprise Associates, explains to LSIPR the firm’s role in supporting medtech innovation, his sweet spot when it comes to projects, and how to balance what is medically relevant with commercial viability.

The future of precision medicine part 2: data is king

International, UK17-07-2018Daniel Lim

In the area of precision medicine, there are questions surrounding what data is needed, how it is used, what it should look like and what concerns there are for patients and society, as Daniel Lim of Kirkland & Ellis reports.

LSIPR 50 2018: An agent of change in healthcare

US16-07-2018

Healthcare investment yields the best returns when focusing on its core aims and forging strong partnerships, James Flynn, managing partner of Deerfield, tells LSIPR.

LSIPR 50 2018: Personalised medicine: the way forward

US13-07-2018

BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.

LSIPR 50 2018: Leading the transformation change

US12-07-2018

Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.

Showing 61 to 70 of 322 results

LSIPR